India, Feb. 3 -- Natco Pharma on Tuesday announced that it has received tentative approval from the US Food and Drug Administration for its generic version of Erdafitinib tablets in strengths of 3 mg, 4 mg, and 5 mg.
The approved product is a generic equivalent of Janssen Biotech Inc's branded drug Balversa. Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....